Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesCancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Askling J et al. – The goal of this study was to determine the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor (anti-TNF) therapies that have proven effective in the treatment of chronic inflammatory conditions. During the first 6 years after the start of anti-TNF therapy in routine care, no overall elevation of cancer risk and no increase with followup time were observed.
Methods- Identified and analyzed for cancer occurrence a national cohort of 6,366 patients with RA who first started anti-TNF therapy between January 1999 and July 2006
- Used national biologics-naive RA cohort (n = 61,160), a cohort of RA patients newly starting methotrexate (n = 5,989), a cohort of RA patients newly starting disease-modifying antirheumatic drug combination therapy (n = 1,838), and general population
- RRs estimated using Cox regression analyses, examining overall RR as well as RR by time since first start of anti-TNF therapy, by duration of active anti-TNF therapy, and by anti-TNF agent received
- During 25,693 person-years of followup in 6,366 patients newly starting anti-TNF, 240 first cancers occurred, yielding an RR of 1.00 (95% confidence interval 0.86-1.15) versus biologics-naive RA cohort, and similar RRs versus other 2 RA comparators
- RRs did not increase with increasing time since the start of anti-TNF therapy, nor with cumulative duration of active anti-TNF therapy
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/20/09
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
Rheumatology, 11/20/09
Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk
Seminars in Arthritis and Rheumatism, 11/20/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
New classification of the shared epitope in rheumatoid arthritis: Impact on the production of various anti-citrullinated protein antibodies
Rheumatology, 11/20/09
Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis
Arthritis Research & Therapy, 11/20/09
Significance of clinical evaluation of the metacarpophalangeal joint in relation to synovial/bone pathology in rheumatoid and psoriatic arthritis detected by magnetic resonance imaging
Journal of Rheumatology, 11/19/09
Sponsor
Article Search
Sponsor